Entelos Announces New Research Contract

    


Entelos Inc.



Entelos, Inc. (LSE: ENTL), a U.S.-based life sciences company using predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that it is extending its technology
applications to conduct research using "virtual consumers" for an undisclosed
customer in Switzerland. This multi-million dollar research contract will focus
on risk assessment and reduction in cardiovascular disease and other disease
areas of interest to the customer. Entelos will receive technology license fees
and R&D funding for the next three years.

"We are pleased to be expanding the use of our powerful simulation technology to
applications in consumer products," stated James Karis, President and CEO of
Entelos. "Our virtual patient populations have already been used successfully
with multiple pharmaceutical customers to test for drug safety and efficacy. In
this new application, we will be expanding its use to test the effects of
'virtual products' on 'virtual consumers,' representations of unique genetic,
biologic, and lifestyle profiles. We can then use our technology to optimize
product designs to improve human health."

For further information please contact:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations            Tel: +1 650 572 5400
KBC Peel Hunt, Ltd (Nominated Advisor and
 Broker)
Capel Irwin                                 Tel +44 (0) 20 4718 8900
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson           Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines and
health-care related consumer products are discovered, developed, and utilized.
The Company leverages its proprietary in silico disease models, "virtual
populations", and toxicology reference systems to develop safer and more
effective drugs for pharmaceutical R&D and to help improve the quality of
health-care related consumer products. Entelos provides customized technology
and research services to global pharmaceutical, health-care, and consumer
products companies in arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization,
and personal care products. The Company is also developing a model in oncology
and is collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024